Key result
Improper use and discontinuation of anticoagulant therapy in a young male with a homozygous Factor V Leiden mutation led to 4 hospital admissions for recurrent venous thromboembolism over 5 years.
Why the study?
Factor V Leiden mutation inherited from both parents is found in only 0.05-0.5% of cases, highlighting the need to examine diagnostics, therapy, and precautions in homozygous patients with recurrent VTE.
Case Report (n=1)
Patients with a homozygous Factor V Leiden mutation are at extremely high risk for recurrent venous thromboembolism and require early diagnosis, patient education, and potentially long-term uninterrupted anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Underscores need for adherence education in homozygous FVL; leaves open optimal long-term strategies pending prospective data.
Šahinović et al. (2021) conducted a case report in Venous thromboembolism (n=1). Anticoagulant therapy was evaluated on Recurrent VTE. Improper use and discontinuation of anticoagulant therapy in a young male with a homozygous Factor V Leiden mutation led to 4 hospital admissions for recurrent venous thromboembolism over 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: